194 related articles for article (PubMed ID: 35912568)
21. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
[TBL] [Abstract][Full Text] [Related]
22. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
23. [Eosinophilic small vessel vasculites (EGPA) a hidden severe asthma comorbitity].
Sturluson OO; Palsson O; Hjaltested E; Ludviksdottir D
Laeknabladid; 2024 Jan; 110(1):28-32. PubMed ID: 38126794
[TBL] [Abstract][Full Text] [Related]
24. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
25. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.
Molina B; Padoan R; Urban ML; Novikov P; Caminati M; Taillé C; Néel A; Bouillet L; Fraticelli P; Schleinitz N; Christides C; Moi L; Godeau B; Knight A; Schroeder JW; Marchand-Adam S; Gil H; Cottin V; Durel CA; Gelain E; Lerais B; Ruivard M; Groh M; Samson M; Moroni L; Thiel J; Kernder A; Cohen Tervaert JW; Costanzo G; Folci M; Rizzello S; Cohen P; Emmi G; Terrier B
Ann Rheum Dis; 2023 Dec; 82(12):1587-1593. PubMed ID: 37734881
[TBL] [Abstract][Full Text] [Related]
27. Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature.
Seccia V; Baldini C; Latorre M; Gelardi M; Dallan I; Cristofani-Mencacci L; Sellari-Franceschini S; Bartoli ML; Bacci E; Paggiaro P
Int Arch Allergy Immunol; 2018; 175(1-2):61-69. PubMed ID: 29393242
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
[TBL] [Abstract][Full Text] [Related]
29. Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
Tsioulos G; Kounatidis D; Vallianou NG; Koufopoulos N; Katsimbri P; Antoniadou A
Am J Med Sci; 2023 Jan; 365(1):93-98. PubMed ID: 35970248
[TBL] [Abstract][Full Text] [Related]
30. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
31. Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients.
Jachiet M; Samson M; Cottin V; Kahn JE; Le Guenno G; Bonniaud P; Devilliers H; Bouillet L; Gondouin A; Makhlouf F; Meaux-Ruault N; Gil H; Bienvenu B; Coste A; Groh M; Giraud V; Dominique S; Godeau B; Puéchal X; Khouatra C; Ruivard M; Le Jeunne C; Mouthon L; Guillevin L; Terrier B;
Arthritis Rheumatol; 2016 Sep; 68(9):2274-82. PubMed ID: 26946346
[TBL] [Abstract][Full Text] [Related]
32. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
Ueno M; Miyagawa I; Aritomi T; Kimura K; Iwata S; Hanami K; Fukuyo S; Kubo S; Miyazaki Y; Nakayamada S; Tanaka Y
Arthritis Res Ther; 2022 Jun; 24(1):159. PubMed ID: 35768825
[TBL] [Abstract][Full Text] [Related]
33. Successful Treatment with Mepolizumab for Coronary Spastic Angina Associated with Eosinophilic Granulomatosis with Polyangiitis.
Takigawa Y; Fujiwara K; Tabuchi I; Kudo K; Hayashi K; Matsumoto S; Omori H; Matsuoka S; Mitsumune S; Watanabe H; Sato A; Sato K; Shibayama T
Intern Med; 2023; 62(16):2389-2393. PubMed ID: 37587056
[TBL] [Abstract][Full Text] [Related]
34. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
[No Abstract] [Full Text] [Related]
35. Low-dose mepolizumab is effective as an add-on therapy for treating long-lasting peripheral neuropathy in patients with eosinophilic granulomatosis with polyangiitis.
Nakamura Y; Fukutomi Y; Sekiya K; Kajiwara K; Kawasaki Y; Fujita N; Nagayama K; Iwata M; Iwamoto K; Yano K; Hamada Y; Watai K; Ryu K; Hayashi H; Kamide Y; Taniguchi M
Mod Rheumatol; 2022 Feb; 32(2):387-395. PubMed ID: 34910206
[TBL] [Abstract][Full Text] [Related]
36. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
[TBL] [Abstract][Full Text] [Related]
37. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
38. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
39. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
[TBL] [Abstract][Full Text] [Related]
40. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study.
Ishii T; Kunishige H; Kobayashi T; Hayashi E; Komatsubara M; Ishii T; Alfonso-Cristancho R; Tamaoki J; Howarth P
Mod Rheumatol; 2023 Dec; ():. PubMed ID: 38100679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
